Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Biomarkers to Detect Endocrine Therapy Resistance

for
Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: All

Age: 18+

Code: NCT06067503

Phase 2, Recruiting
Active & Responsive

A Study of PHST001 in Advanced Solid Tumors

for
Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer,
Location: Boston MA, New Haven CT, Lake Success NY, New York NY,
Sponsor: Pheast Therapeutics

Sex: All

Age: 18+

Code: NCT06840886

Phase 1, Recruiting
Active & Responsive

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

for
Colorectal Cancer, Advanced/Metastatic Solid Tumor,
Location: Scottsdale AZ
Sponsor: LTZ Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07878988

Phase 1, Recruiting
Active & Responsive

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

for
Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT07675967

Recruiting
Active & Responsive

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

for
Breast Cancer, Residual Disease,
Location: Chapel Hill NC, Birmingham AL
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT07069595

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

The Florida ASCENT Study

for
Cancer, Food Deprivation, Food Habits, Food Selection,
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT07042243

Recruiting
Active & Responsive

GTB-5550 in Advanced Solid Tumors

for
Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT07541573

Phase 1, Recruiting
Active & Responsive

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

for
Breast Cancer, Endometrial Cancer, Ovarian Cancer,
Location: Boston MA, Fairfax VA, Orlando FL, Cleveland OH,
Sponsor: Terremoto Biosciences Inc.

Sex: All

Age: 18+

Code: NCT07109726

Phase 1, Phase 2, Recruiting
Active & Responsive

Efficacy of Point Of Service Testing in MBC

for
Metastatic Cancer, Breast Cancer
Location: Kansas City KS
Sponsor: University of Kansas Medical Center

Sex: All

Age: 18+

Code: NCT03983577

Recruiting
Active & Responsive

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

for
Advanced Malignant Solid Neoplasm,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18+

Code: NCT06320405

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

for
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Location: Boston MA, New York NY, Philadelphia PA, Baltimore MD,
Sponsor: Nuvalent Inc.

Sex: All

Age: 12+

Code: NCT05384626

Phase 1, Phase 2, Recruiting
Active & Responsive

Met Non Small Cell Cancer Registry (MOMENT)

for
Cancer
Location: Quebec, Ottawa, Fort Lauderdale FL, Toronto,
Sponsor: EMD Serono Research & Development Institute, Inc.

Sex: All

Age: 0+

Code: NCT05376891

Recruiting
Active & Responsive

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for
Breast Neoplasms
Location: Rimouski, Boston MA, Quebec, Stony Brook NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06312176

Phase 3, Recruiting
Active & Responsive

Feasibility of a Habit-Based Intervention to Reduce Sedentary Behaviour in Cancer Survivors

for
Cancer, Sedentary Behaviour
Location: Toronto
Sponsor: University of Toronto

Sex: All

Age: 18+

Code: NCT07694479

Recruiting
Active & Responsive

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

for
Triple Negative Breast Cancer (TNBC)
Location: Grand Rapids MI, Nashville TN, San Antonio TX,
Sponsor: Immunomic Therapeutics, Inc.

Sex: Female

Age: 18+

Code: NCT07652242

Phase 1, Recruiting
Active & Responsive

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for
Intestinal Neoplasms, Gastrointestinal Neoplasms,
Location: Topsham ME, Westbrook ME, Boston MA, Newton MA,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07222800

Phase 3, Recruiting
Active & Responsive

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

for
Hematopoietic Cell Transplantation Recipient, Leukemia,
Location: Boston MA, Providence RI, Hartford CT, New Haven CT,
Sponsor: Children's Oncology Group

Sex: All

Age: 0+

Code: NCT00736749

Recruiting
Active & Responsive

HER2 Vaccine for Locally Advanced Breast Cancer

for
Breast Cancer, HER2-positive Breast Cancer
Location: Indianapolis IN
Sponsor: Pravin T.P Kaumaya

Sex: All

Age: 18+

Code: NCT06949410

Phase 1, Recruiting
Active & Responsive

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

for
Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT05196087

Recruiting
Active & Responsive

HER-2 B Cell Peptide Vaccine

for
Metastatic Breast Cancer, HER2-positive Breast Cancer,
Location: Indianpolis IN
Sponsor: Pravin T.P Kaumaya

Sex: All

Age: 18+

Code: NCT06414733

Phase 1, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial